Late Metastasis Development in Two Cases of Small Choroidal Melanoma
Authors:
Z. Svetlošáková 1; A. Malclès 2; P. Pommier 3; V. Krásnik 1; J. D. Grange 2
Authors‘ workplace:
Klinika oftalmológie LFUK, Bratislava
prednosta doc. MUDr. Vladimír Krásnik, PhD.
1; Klinika oftalmológie, Hôpital de la Croix-Rousse, Claude Bernard Université, Lyon, Francúzsko
prednosta prof. Philippe Denis, MD, PhD.
2; Oddelenie rádioterapie, Centre Léon Bérard, Lyon, Francúzsko
vedúci oddelenia Christian Carrie, MD
3
Published in:
Čes. a slov. Oftal., 69, 2013, No. 3, p. 134-137
Category:
Case Report
Čiastočne prezentované na XVII. Výročnom kongrese Slovenskej oftalmologickej spoločnosti, 7.10. 2011, Bojnice, Slovensko
Overview
Purpose:
To present data pointing out that small tumour size might not be a sufficient predictor of good prognosis of choroidal melanoma and present a new promising therapy of hepatic metastasis.
Methods:
Retrospective, noncomparative case report of two patients with small choroidal melanoma.
Results:
Two cases of small choroidal melanoma which developed metastases are described. Both patients underwent radiotherapy of the primary tumour. Metastases were treated by combined therapy in patient 1 while in patient 2 a new therapeutic modality of stereotactic radiotherapy, Cyberknife, was applied. Patient 1 died from metastatic spread 7,6 years after primary therapy despite a very good local tumour control. Patient 2 died 11,3 years after primary therapy due to intercurrent disease with a very good local eye findings and hepatic metastasis in regression.
Conclusion:
Choroidal melanoma of a small size can develop into metastatic disease even long time after satisfactory primary treatment. Further studies are required to assess the risk factors of metastatic spread in small uveal melanomas. Cyberknife stereotactic radiotherapy seems to be a promising therapeutic method of a solitary hepatic metastasis.
Key words:
choroidal melanoma, metastasis, prognostic factors, stereotactic radiotherapy
Sources
1. Mortality in patients with small choroidal melanoma. COMS report no. 4. The Collaborative Ocular Melanoma Study Group, Arch Ophthalmol, 115; 1997, 7: 886–93.
2. Bedikian, A.Y.: Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin, 46; 2006, 1: 151–66.
3. Dewas, S., Mirabel, X., Kramar, A. et al.: Stereotactic body radiation therapy for liver primary and metastases: The Lille experience. Cancer Radiother, 16; 2012, 1: 58-69.
4. Diener-West, M., Reynolds, S.M., Agugliaro, D.J. et al.: Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol, 123; 2005, 12: 1639–43.
5. Edelhauser, G., Schicher, N., Berzaczy, D. et al.: Fotemustine chemoembolization of hepatic metastases from uveal melanoma: a retrospective single-center analysis. AJR Am J Roentgenol, 199; 2012, 6: 1387–92.
6. Eskelin, S., Pyrhonen, S., Summanen, P. et al.: Tumour doubling times in metastatic malignant melanoma of the uvea: tumour progression before and after treatment. Ophthalmology, 107, 2000, 8: 1443–9.
7. Fumagalli, I., Bibault, J.E., Dewas, S. et al.: A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases. Radiat Oncol, 7; 2012, 164.
8. Furdová, A., Slezák, P., Chorváth, M. et al.: No differences in outcome between radical surgical treatment (enucleation) and stereotactic radiosurgery in patients with posterior uveal melanoma. Neoplasma, 57; 2010, 4: 377–81.
9. Furdová, A., Strmeň, P., Šramka, M.: Complications in patients with uveal melanoma after stereotactic radiosurgery and brachytherapy. Bratisl Lek Listy, 106; 2005, 12: 401–6.
10. Furdová, A., Strmeň, P., Waczulíková, I. et al.: One-day session LINAC-based stereotactic radiosurgery of posterior uveal melanoma. Eur J Ophthalmol, 22; 2012, 2: 226– 235.
11. Isager, P., Ehlers, N., Overgaard, J.: Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas, Acta Ophthalmol Scand, 82; 2004, 5: 517–25.
12. Klingenstein, A., Haug, A.R., Zech, C.J. et al.: Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. Cardiovasc Intervent Radiol, 36; 2013, 1: 158–65.
13. Kodjikian, L., Grange, J.D., Baldo, S. et al.: Prognostic factors of liver metastases from uveal melanoma. Graefes Arch Clin Exp Ophthalmol, 243; 2005, 10: 985–93.
14. Kodjikian, L., Grange, J.D., Rivoire, M.: Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy. Graefes Arch Clin Exp Ophthalmol, 243; 2005, 6: 622–4.
15. Kujala, E., Makitie, T., Kivela, T.: Very long-term prognosis of patients with malignant uveal melanoma, Invest Ophthalmol Vis Sci, 44, 2003, 11: 4651–9.
16. Rivoire, M., Kodjikian, L., Baldo, S. et al.: Treatment of liver metastases from uveal melanoma. Ann Surg Oncol, 12; 2005, 6: 422–8.
17. Seregard, S., Kock, E.: Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of long-term survival with minimized loss to follow-up. Acta Ophthalmol Scand, 73; 1995, 4: 340–4.
18. Shields, C.L., Furuta, M., Thangappan, A. et al.: Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol, 127; 2009, 8: 989–98.
19. Shields, C.L., Shields, J.A., Kiratli, H. et al.: Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology, 102; 1995, 9: 1351–61.
20. Singh, A.D., Borden, E.C.: Metastatic uveal melanoma. Ophthalmol Clin North Am, 18; 2005, 1: 143–50.
21. Virgili, G., Gatta, G., Ciccolallo, L. et al.: Survival in patients with uveal melanoma in Europe. Arch Ophthalmol, 126; 2008, 10: 1413–8.
Labels
OphthalmologyArticle was published in
Czech and Slovak Ophthalmology
2013 Issue 3
Most read in this issue
- Glaucoma Therapy – Current Overview of Data and Information
- New Methods of the Treatment of Retinal Dystrophies
- The Potential use of Honey in Ophthalmology
- Surgical Treatment of the Idiopatic Macular Hole – our Experience